Payload Information

General Information of This Payload
Payload ID
PAY0PNJFX
Name
AC225
Synonyms
AC225
   Click to Show/Hide
Target(s) .
 Target Info 
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half-maximal effective concentration (EC50) 2.8 nCi/ml
SK-OV-3 cells
Ovarian serous cystadenocarcinoma
CVCL_0532 
[1]
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Lintuzumab Ac-225 [Phase 2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Objective Response Rate (ORR)
67.00%
Patients Enrolled
Patients with more than 25% of leukemic blasts must have been CD33 positive by flow cytometry.
Administration Dosage
Induction consisted of G-CSF, 300 mg/d, given D1-6, cladribine 5 mg/m2, given D2-6, cytarabine 2 ug/m2, given D2-6, and mitoxantrone 10 mg/m2, given D2-4. Lintuzumab Ac225 was administered as a single dose on either day 7, 8, or 9 with a dose of 0.25 uCi/kg, 0.50 uCi/kg, or 0.75 uCi/kg.
Related Clinical Trial
NCT Number NCT03441048  Phase Status Phase 1
Clinical Description
A phase 1 study of lintuzumab-Ac225 in combination with CLAG-M chemotherapy in patients with relapsed/refractory acute myeloid leukemia.
Experiment 2 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT03932318  Phase Status Phase 1
Clinical Description
A phase 1/2 study of venetoclax and azacitidine and lintuzumab-Ac225 in patients with refractory or relapsed AML.
Experiment 3 Reporting the Activity Date of This ADC [4]
Related Clinical Trial
NCT Number NCT03867682  Phase Status Phase 1
Clinical Description
A phase 1/2 study of venetoclax and lintuzumab-Ac225 in patients with refractory or relapsed AML.
Experiment 4 Reporting the Activity Date of This ADC [5]
Related Clinical Trial
NCT Number NCT02998047  Phase Status Phase 1
Clinical Description
A phase 1 study of lintuzumab-Ac225 in patients with refractory multiple myeloma.
Experiment 5 Reporting the Activity Date of This ADC [6]
Related Clinical Trial
NCT Number NCT02575963  Phase Status Phase 1
Clinical Description
A phase 1/2 study of lintuzumab-Ac225 in older patients with untreated acute myeloid leukemia.
References
Ref 1 Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003 Aug 15;63(16):5084-90.
Ref 2 TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). J Clin Oncol. 2023 41:16_suppl, 9004-9004.
Ref 3 A Phase I/II Study of Venetoclax and Azacitidine and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML, NCT03932318
Ref 4 A Phase I/II Study of Venetoclax and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML, NCT03867682
Ref 5 A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma, NCT02998047
Ref 6 A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia, NCT02575963

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.